Beta-Nicotinamide Mononucleotide (NMN) Market Report Overview
-
Request a Free Sample to learn more about this report
global beta-nicotinamide mononucleotide (nmn) market size was USD 356.1 million in 2022 and market is projected to touch 1867.77 Million by 2031, exhibiting a CAGR of 20.2 % during the forecast period.
The formation of the coenzyme nicotinamide adenine dinucleotide (NAD+), which is essential for many biological functions such as energy metabolism and DNA repair, begins with the molecule nicotinamide mononucleotide (NMN). As we get older, our body's NAD+ levels decline, which is thought to speed up ageing and cause age-related disorders. A sequence of chemical processes transforms NMN, which is a precursor to NAD+, into NAD+. The most bioavailable and efficient form of NMN for increasing NAD+ levels is thought to be beta-nicotinamide mononucleotide (-NMN). NAD+ levels have been found to rise in a variety of tissues and organs, including the brain, liver, and muscle, when NMN or -NMN is supplemented.
COVID-19 Impact: Pandemic Hamper the Demand of Beta-Nicotinamide Mononucleotide (NMN) to Market Growth
NMN may have potential benefits in supporting the immune system and reducing inflammation, which could be beneficial in the context of COVID-19. NAD+ levels have been shown to decrease with age and in various chronic diseases, including viral infections, and this may contribute to impaired immune function. NMN supplementation has been found to increase NAD+ levels and improve immune functions. One study found that NMN administration in aged mice improved their immune function and reduced the severity of influenza infection.
Latest Trends
"NMN is the Growing Quantity of Studies and Clinical Trials Research to Support Market Expansion"
The most recent development in NMN research is the rise in clinical trials and studies looking at its possible advantages. An increasing body of research suggests that NMN may also improve metabolic health, enhance cardiovascular health, and reduce inflammation in addition to its anti-aging properties. Several clinical experiments are now being conducted to investigate the security and effectiveness of NMN supplementation in humans.
Beta-Nicotinamide Mononucleotide (NMN) Market Segmentation
-
Request a Free Sample to learn more about this report
- By Type Analysis
According to type, the beta-nicotinamide mononucleotide (NMN) market can be segmented content greater than or equal to 98% and content less than 98%.
In terms of type, the content greater than or equal to 98% is anticipated to be the largest segment during the forecast period.
- By Application Analysis
Based on application, the beta-nicotinamide mononucleotide (NMN) market can be divided into health care products, cosmetics, and others.
In terms of application, the health care products market is projected to hold the largest beta-nicotinamide mononucleotide (NMN) market share through 2031.
Driving Factors
"Anti-Aging Properties Improvements in Physical will Drive Market Growth "
One of the primary driving factors behind the increased interest in Beta-Nicotinamide Mononucleotide (NMN) is its potential as an anti-aging supplement. NMN has been shown to increase NAD+ levels in various tissues and organs, leading to improvements in physical and cognitive function, as well as potential reductions in age-related diseases.
"Clinical Trials and Research on Anti-Aging Techniques Will Help the Market Flourish"
The increasing number of studies and clinical trials investigating the potential benefits of NMN is driving interest in this supplement. There is growing evidence that NMN may have a range of potential benefits, including metabolic health, cardiovascular health, and reducing inflammation. The availability of NMN supplements has increased in recent years, with many companies now offering NMN supplements in various forms, including capsules, powders, and sublingual tablets. This has made it easier for individuals to access and try this supplement.
Restraining Factors
"Inadequate Regulation and a Lack of Long-Term Safety Data Will Impede Market Growth"
While beta-nicotinamide mononucleotide (NMN) has been shown to be generally safe in animal studies and short-term human trials, there is a lack of long-term safety data. This has raised concerns about potential side effects and the safety of using NMN supplements or beta-nicotinamide mononucleotide (NMN) over an extended period. The supplement industry is not well-regulated, and there are concerns about the quality and consistency of NMN supplements. This can make it difficult for consumers to know which products are safe and effective.
Beta-Nicotinamide Mononucleotide (NMN) Market Regional Insights
-
Request a Free Sample to learn more about this report
"The North America Region will Dominate Market Due to Strong Demand for Anti-Aging Supplements "
North America is the largest market for beta-nicotinamide mononucleotide (NMN), being the primary consumer. The region has a large aging population, which has increased interest in anti-aging supplements like NMN. The region is also home to many supplement companies, which have contributed to the availability of beta-nicotinamide mononucleotide (NMN) in the market.
Asia Pacific is expected to be the fastest-growing market for beta-nicotinamide mononucleotide (NMN). The region has a large aging population, and there is an increasing interest in anti-aging supplements. Additionally, there is a long history of using traditional medicines and supplements in the region, which has contributed to the popularity of beta-nicotinamide mononucleotide (NMN).
Key Industry Players
"Adoption Aluminum Recycling Services by Key Players Influencing Market Development"
The top key players in the market are GeneHarbor, Herbalmax, Genex Formulas, Shinkowa Pharmaceutical, Maac10 Formulas, EffePharm. Most of the top players hold the beta-nicotinamide mononucleotide (NMN) market shares. In addition, the strategies to develop new technologies, capital investment in R&D, improve product quality, acquisitions, mergers, and compete for the beta-nicotinamide mononucleotide (NMN) market growth in the competition help them to perpetuate their position and value in the market. Besides, collaboration with other companies & extensive possession of market shares by the key players stimulates the beta-nicotinamide mononucleotide (NMN) market.
List of Market Players Profiled
- GeneHarbor (China)
- Herbalmax (U.S.)
- Genex Formulas (U.S.)
- Shinkowa Pharmaceutical (Japan)
- Maac10 Formulas (U.S.)
- EffePharm (China)
- Bontac (U.S.)
- CELFULL (China)
- Kingdomway (China)
Report Coverage
This report examines an understanding of the beta-nicotinamide mononucleotide (NMN) market’s size, share, growth rate, segmentation by type, application, key players, and previous and current market scenarios. The report also collects the market’s precise data and forecasts by market experts. Also, it describes the study of this industry’s financial performance, investments, growth, innovation marks, and new product launches by the top companies and offers deep insights into the current market structure, competitive analysis based on key players, key driving forces, and restraints that affect the demand for growth, opportunities, and risks.
Furthermore, the post-COVID-19 pandemic’s effects on international market restrictions and a deep understanding of how the industry will recover, and strategies are also stated in the report. The competitive landscape has also been examined in detail to provide clarification of the competitive landscape.
This report also discloses the research based on methodologies that define price trend analysis of target companies, collection of data, statistics, target competitors, import-export, information, and previous years’ records based on market sales. Moreover, all the significant factors which influence the market such as small or medium business industry, macro-economic indicators, value chain analysis, and demand-side dynamics, with all the major business players have been explained in detail. This analysis is subject to modification if the key players and feasible analysis of market dynamics change.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 356.1 Million in 2022 |
Market Size Value By |
US$ 1867.77 Million by 2031 |
Growth Rate |
CAGR of 20.2% from 2022 to 2031 |
Forecast Period |
2024-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
What value is the global beta-nicotinamide mononucleotide (NMN) market expected to touch by 2031?
The global beta-nicotinamide mononucleotide (NMN) market is expected to touch USD 1867.77 Million by 2031.
-
What CAGR is the beta-nicotinamide mononucleotide (NMN) market expected to exhibit during 2024-2031?
The beta-nicotinamide mononucleotide (NMN) market is expected to exhibit a CAGR of 20.2% over 2024-2031.
-
Which are the driving factors of the beta-nicotinamide mononucleotide (NMN) market?
NMN is the growing quantity of studies and clinical trials research are the driving factor of the beta-nicotinamide mononucleotide (NMN) market.
-
Which are the top companies operating in the beta-nicotinamide mononucleotide (NMN) market?
GeneHarbor, Herbalmax, Genex Formulas, Shinkowa Pharmaceutical, Maac10 Formulas, EffePharm are the top operating companies in the beta-nicotinamide mononucleotide (NMN) market.